Presentation is loading. Please wait.

Presentation is loading. Please wait.

An assessment by the Statin Liver Safety Task Force: 2014 update

Published byNeil Henderson Modified over 6 years ago

Similar presentations

Presentation on theme: "An assessment by the Statin Liver Safety Task Force: 2014 update"— Presentation transcript:

1 An assessment by the Statin Liver Safety Task Force: 2014 update
Harold Bays, MD, FNLA, David E. Cohen, MD, PhD, Naga Chalasani, MBBS, Stephen A. Harrison, MD, COL, MC  Journal of Clinical Lipidology  Volume 8, Issue 3, Pages S47-S57 (May 2014) DOI: /j.jacl Copyright © 2014 National Lipid Association Terms and Conditions

2 Figure 1 Comprehensive approach to patients with elevated liver blood testing (transaminases <3 times the upper limits of normal).23,24 Journal of Clinical Lipidology 2014 8, S47-S57DOI: ( /j.jacl ) Copyright © 2014 National Lipid Association Terms and Conditions

3 Figure 2 Comprehensive approach to patients with elevated liver blood testing (transaminases >3 times the upper limits of normal). Journal of Clinical Lipidology 2014 8, S47-S57DOI: ( /j.jacl ) Copyright © 2014 National Lipid Association Terms and Conditions

Download ppt "An assessment by the Statin Liver Safety Task Force: 2014 update"

Similar presentations

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.
Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements 

Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements 
Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,
A clinician's guide to statin drug-drug interactions

A clinician's guide to statin drug-drug interactions
Wayne S. Dysinger, MD, MPH, James M. Pappas, MD, MBA 

Wayne S. Dysinger, MD, MPH, James M. Pappas, MD, MBA 
Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.
The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1- year growth data  Steve E. Humphries, PhD, FRCP, Jackie Cooper,

The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1- year growth data  Steve E. Humphries, PhD, FRCP, Jackie Cooper,
Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart.

Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart.
Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.
An assessment by the Statin Cognitive Safety Task Force: 2014 update

An assessment by the Statin Cognitive Safety Task Force: 2014 update
An assessment by the Statin Muscle Safety Task Force: 2014 update

An assessment by the Statin Muscle Safety Task Force: 2014 update
Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.

Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.
An assessment by the Statin Diabetes Safety Task Force: 2014 update

An assessment by the Statin Diabetes Safety Task Force: 2014 update
Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,
Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men  Gloria Lena Vega, PhD, Scott M. Grundy,

Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men  Gloria Lena Vega, PhD, Scott M. Grundy,
A review of PCSK9 inhibition and its effects beyond LDL receptors

A review of PCSK9 inhibition and its effects beyond LDL receptors
Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,
Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.
Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome  Richard M. Turner,

Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome  Richard M. Turner,
Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results.

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results.

Similar presentations

Ads by Google